Your search for tofacitinib returned 2 results

Statistically significant improvements were shown 3 months vs. placebo with tofacitinib, in this new study

Xeljanz and Xeljanz XR are Janus kinase (JAK) inhibitors indicated to treat moderately to severely active rheumatoid arthritis when methotrexate therapy is inadequate.